ASAP Data Repository

There is a newer version of the record available.

Published September 3, 2022 | Version v1
Journal article Open

LRRK2-G2019S SYNERGIZES WITH AGEING AND LOW-GRADE INFLAMMATION TO PROMOTE GUT AND PERIPHERAL IMMUNE CELL ACTIVATION THAT PRECEDE NIGROSTRIATAL DEGENERATION

Authors/Creators

  • 1. Institut Imagine, INSERM UMR1163 Paris Cite' University, 24 boulevard du Montparnasse, 75015, Paris, France
  • 2. Neuropharmacology Laboratory, Oasi Research Institute-IRCCS, Troina-Italy
  • 3. Biomedical and Biotechnological Sciences, Pharmacology Section, University of Catania-Italy
  • 4. Mitochondria and Inflammation in Neurodegenerative Diseases, DZNE, Tübingen-Germany
  • 5. NMI Natural and Medical Sciences Institute, University of Tübingen, Reutlingen-Germany
  • 6. Department of Clinical and Experimental Medicine, Mathematics and Computer Science Section, University of Catania-Italy

Description

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most frequent cause of familial Parkinson's disease (PD). The incomplete penetrance of LRRK2 mutations suggest that additional hits are required for disease onset. We hypothesized that chronic low-grade inflammation interacts with LRRK2 G2019S, a the most frequent PD-associated mutation, to activate peripheral and central immune reactions and drive age-dependent neurodegeneration. We exposed wild-type and LRRK2 G2019S mice to a low chronic dose of lipopolysaccharide and performed a longitudinal analysis of central and peripheral immune reactions and neurodegeneration. Low-dose inflammation triggered nigrostriatal degeneration, peripheral monocyte infiltration, and astro-/microgliosis. LRRK2 G2019S mice showed an early dysregulation of peripheral cytokines as well as increased CD4+ T-cell infiltration and α-synuclein aggregation in the colon. Peripheral immune activation and colonic α-synuclein aggregation preceded brain inflammation and degeneration. Our study suggests an early role of the peripheral immune system and the gut in LRRK2 PD and provides a novel model to study early therapeutic immune targets and biomarkers.

Files

LIST OF PRODUCTS (3).pdf

Files (63.6 MB)

Name Size Download all
md5:4519e304d86dbf71a09c7ef4a1ab1b2b
219.2 kB Preview Download
md5:28f38ced3df93d543edb3969036d0312
41.2 MB Preview Download
md5:e98019fe590da028ad09d81d4990e595
2.5 MB Preview Download
md5:6ea5b0de2db68de6aeee2b4af4394183
721.5 kB Preview Download
md5:52904ce260ff28700af65af85585c2ff
18.9 MB Preview Download